Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.
Saved in:
| Title: | Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. |
|---|---|
| Authors: | Harter, P.1,2 (AUTHOR) P.Harter@kem-med.com, Trillsch, F.2,3 (AUTHOR), Okamoto, A.4,5 (AUTHOR), Reuss, A.6,7 (AUTHOR), Kim, J.-W.8,9 (AUTHOR), Rubio-Pérez, M.J.10,11 (AUTHOR), Vardar, M.A.12,13,14 (AUTHOR), Scambia, G.15,16 (AUTHOR), Trédan, O.17,18 (AUTHOR), Nyvang, G.-B.19,20 (AUTHOR), Colombo, N.21,22 (AUTHOR), Bidziński, M.23,24 (AUTHOR), Grimm, C.25,26 (AUTHOR), Lheureux, S.27,28 (AUTHOR), Van Nieuwenhuysen, E.29,30 (AUTHOR), Heitz, F.2,31,32 (AUTHOR), Wenham, R.M.33,34 (AUTHOR), Nishio, S.5,35 (AUTHOR), Lim, M.C.9,36 (AUTHOR), Marquina, G.11,37 (AUTHOR) |
| Source: | Annals of Oncology. Apr2026, Vol. 37 Issue 4, p503-520. 18p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.11.020 |
